No Data
No Data
No Data
Hanyu Medical IPO, leading product ValveClamp reshapes TMV market pattern
Hanyu Medical has been listed and heard on the Hong Kong Stock Exchange. The company is a medical technology company mainly dedicated to R&D, production and sales of interventional cardiac devices.
China's mitral “unicorn” begins countdown to listing to explore the core logic of long-term ownership of Hanyu Healthcare
The Zhitong Finance App learned that on September 13, Hanyu Medical, a leader in the field of structural heart disease interventional treatment in China, published a collection of post-hearing materials, which meant that Hanyu Medical began the countdown to its listing. When Hanyu Medical comes to market, investors need to explore the company's deep investment value from the perspective of major product pipelines, strong R&D capabilities, and business prospects from behind its strong technology development capabilities. TMVR is taking the lead in treatment and raising industry entry barriers Hanyu Medical, founded in 2016, is committed to the development and commercialization of innovative medical devices in the field of structural heart disease. It is the first batch of development in China
Hanyu Medical passed the Hong Kong Stock Exchange hearing. Yunfeng Fund is a shareholder and focuses on medical devices in the field of structural heart disease
Recently, according to the Hong Kong Stock Exchange, Shanghai Hanyu Medical Technology Co., Ltd. passed the Hong Kong Stock Exchange listing hearing, and CICC and Citi are its co-sponsors. According to public information, Hanyu Medical was founded in 2016 and is a medical device R&D and commercialization enterprise focusing on structural heart diseases. Meanwhile, in 2019, Hanyu Medical established a subsidiary, Xinyu Pet Medicine, to expand its business into the field of interventional medical devices for pets. Hanyu Medical's core product is ValveCLAMP, which is mainly suitable for treating primary and secondary mitral valve repair surgery for mitral valve reflux disease. According to the prospectus, this property
Yunfeng Fund invests in shares, cardiac medical device vendor Hanyu Medical passes Hong Kong stock listing hearing | IPO News
Mitral valve repair (TMVR) cardiac medical device vendor Shanghai Hanyu Medical Technology Co., Ltd. (Hanyu Medical for short) recently passed the Hong Kong Stock Exchange listing hearing. CICC and Citigroup are the company's joint sponsors. According to the prospectus of an innovative medical device developer in the heart field, Hanyu Medical, established in 2016, is a domestic platform-based innovative medical device R&D and industrialization enterprise. The company is committed to the development and commercialization of innovative medical devices in the field of structural heart disease, with a particular focus on China's mitral valve intervention (TMV) market (which can be subdivided into mitral valve replacement (TMVR) and mitral valve repair (TMVR))
Hanyu Medical passed the Hong Kong Stock Exchange listing hearing. V-clamp, a mitral valve reflux interventional device, leverages the emerging blue ocean
Hanyu Medical heard through the Hong Kong Stock Exchange how blockbuster products clamped into the hundreds of billions of mitral valve treatment market.
Hanyu Medical was founded in 2016 and has completed six rounds of financing from 2017 to March 2021. Investors include Yunfeng Fund, Oriental Securities, CITIC Industrial Fund, Zhejiang Merchants Innovation Capital and other institutions.
No Data